TRACON Pharmaceuticals Inc

+0.01 (+0.27%)
Products, Strategic Combinations, Regulatory

TRACON Pharmaceuticals Inc And Eucure BiopharmaAnnounce Partnership For Development Of Clinical Stage CTLA-4 Antibody YH001

Published: 10/11/2021 15:52 GMT
TRACON Pharmaceuticals Inc (TCON) - Tracon Pharmaceuticals and Eucure Biopharma, a Subsidiary of Biocytogen, Announce Partnership for Development of Clinical Stage Ctla-4 Antibody Yh001.
Tracon Pharmaceuticals Inc - Intends to Initiate a Phase 1 Trial of Yh001 in Combination With Envafolimab in Soft Tissue Sarcoma.
Tracon Pharmaceuticals Inc - to Study Yh001 in Multiple Other Selected Tumor Types.
Tracon Pharmaceuticals Inc - Tracon Will Bear Costs of Clinical Trials and Eucure Biopharma Will Supply Yh001.
Tracon Pharmaceuticals - Going Forward, Intend to Use Yh001 Rather Than Yervoy in Our Future Dual Checkpoint Inhibition Trials in Sarcoma.
Tracon Pharmaceuticals Inc - Will Owe Eucure Biopharma Escalating Double Digit Royalties on Net Sales.
Tracon - Will Be Responsible for Clinical Development and Commercialization of Yh001 in Multiple Oncology Indications in North America.